Elevated u-sCD163 levels are associated with more active disease, macrophage infiltration, crescent formation, and poor response to supportive care alone, whereas reductions in u-sCD163 following glucocorticoid therapy correspond to improved outcomes and reduced risk of kidney disease progression. This evidence concerns the gene CD163 and kidney disorder.